New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Take the survey

›ETF Issuers›Amplify ETFs›THNR

THNR

Amplify Weight Loss Drug & Treatment ETF

Passive ETF Equity Theme: Tomorrow's Treatments

Not rated

The THNR Exchange Traded Fund (ETF) is provided by Amplify ETFs. It is built to track an index: VettaFi Weight Loss Drug & Treatment Index. The THNR ETF provides physical exposure, so by buying it you actually own parts of all the 20 underlying holdings. This share class generates a stream of income by distributing dividends.

$25.93

-$0.31 (-1.20%) 3 days ago

7:49 PM 07/10/26 Open

1D price range

$25.89$25.99

52W price range

$21.94$26.73

YTD Perf.

+2.75%

YTD Flows

Annualized volatility

Fund AuM

€3.9M

Share class AuM

€3.9M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

US0321085328

TER

0.59%

Inception date

5/21/2024

Issuer

Amplify ETFs

Benchmark

VettaFi Weight Loss Drug & Treatment Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

No content available for this fund

API

PerformanceDec 31, 2025 - Jul 10, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 05/31/26

Healthcare

98.80%

Unavailable

1.20%

Latest THNR news

Ozempic and Weight Loss Drug ETFs Back in Spotlight After Key Earnings Results

Moving Markets · August 12, 2024

FAQ about THNR

THNR is a Passive ETF. This ETF provides exposure to Equities.

THNR tracks the VettaFi Weight Loss Drug & Treatment Index - USD, through a full replication replication method.

THNR carries a total expense ratio (TER) of 0.59%, indicating the annual cost for holding the fund.

THNR was introduced to the market on May 21, 2024. It trades on United States

Amplify Weight Loss Drug & Treatment ETF, THNR, is provided by Amplify ETFs. Learn more about Amplify ETFs here.

THNR oversees €3.9M in assets as of July 10, 2026.

THNR follows a distributing dividend policy, meaning it pays out income to investors. As of July 10, 2026, its 12-month trailing yield was 1.60%.

As of May 31, 2026, THNR has significant geographic allocations in USA, Denmark and China.

As of May 31, 2026, THNR focuses largely on Healthcare.

As of May 31, 2026, THNR holds 20 positions in its portfolio, with 90.83% of assets concentrated in its top 15 holdings.

As of May 31, 2026, THNR top three holdings include Novo Nordisk A/S, Eli Lilly & Co. and Arrowhead Pharmaceuticals, Inc..

The base currency of THNR is USD.

Top 10 holdings

Data as of 05/31/26

Novo Nordisk A/S

14.39%

Eli Lilly & Co.

13.48%

Arrowhead Pharmaceuticals, Inc.

6.19%

Amgen, Inc.

6.02%

Regeneron Pharmaceuticals, Inc.

5.60%

Chugai Pharmaceutical Co., Ltd.

5.24%

Roche Holding AG

5.15%

Merck & Co., Inc.

5.05%

Innovent Biologics, Inc.

4.88%

AstraZeneca PLC

4.76%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

The ETF Industry Is Evolving Fast

Amplify Weight Loss Drug & Treatment ETF

FAQ about THNR

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US